A

Adaptimmune Therapeutics plc

D
ADAP
USD
-0.0586
(-7.0585%)
Market Closed
13,723.00
Volume
-0.80502
EPS
-
Div Yield
-2.143333
P/E
197,333,185.36
Market Cap
Today
-7.0585%
1 Week
7.107%
1 Month
-14.834%
6 Months
-29.855%
12 Months
33.103%
Year To Date
-2.366%
All Time
0%
News

Treasury Yields Decline as Market Anticipates Fed Rate Cuts

26.08.2024
Economy news

Novo Nordisk Surges in Profit and Sales

02.05.2024
Stocks news
More
Related Instruments
L
LINK
-0.47
(-8.2168%)
USD
E
EOS
0.18
(0.7881%)
USD
T
TRX
0.0048
(1.2632%)
USD

Title:
Adaptimmune Therapeutics plc

Sector:
Healthcare
Industry:
Biotechnology
Adaptimmune Therapeutics PLC is a clinical-stage biopharmaceutical company. It focused on providing novel cell therapies to patients, particularly in solid tumors. It has developed a comprehensive proprietary platform that enables it to identify cancer targets, find and genetically engineer T-cell receptors, and produce TCR therapeutic candidates for administration to patients. Its programs include MAGE-A4 SPEAR T-cell therapy, NY-ESO SPEAR T-cell, CD70 and others for multiple cancer types.
Do you need help or have a question?
Contact Us